Flexible Contraceptive Ring Lasts for Whole Year

It is placed vaginally for 21 days and removed for the next seven. When not in use, it is washed and stored in a compact case, withstanding temperatures of up to 30°C, an important consideration for distribution and use in low-resource settings.

Results of the Phase 3 trial, which enrolled a total of 2,308 women across 27 study sites in the United States, Latin America, Europe, and Australia, showed that Annovera was 97.3% effective in preventing pregnancy when used as directed, with a similar risk profile to other combined hormonal contraceptives. Similarly, a boxed warning related to increased cardiovascular risk warns users who smoke. As yet, Annovera has not been adequately evaluated in women with a body mass index (BMI) greater than 29 kg/m2.

“Nearly half of all pregnancies in the United States are unintended, which can increase health risks for mom and baby,” said Julia Bunting, president of the Population Council. “For more than 60 years, the Population Council has been at the vanguard of global efforts to develop innovative family planning methods that meet women’s needs. Having a single contraceptive system that provides a full year of protection while under a woman’s control could be a game-changer for some women.”

Annovera is the sixth contraceptive technology that Population Council researchers have developed to address family planning needs around the world and brought to market through commercialization agreements, which are in use by an estimated 170 million women worldwide. Other contraceptives developed by the Population Council include the copper intrauterine device (IUD) ParaGard; the Mirena intrauterine system; the contraceptive implants Norplant and Jadelle; and Progering, a contraceptive vaginal ring for breastfeeding women.

Related Links:
Population Council